In vitro experiments using B16F10 melanoma and human melanoma cells showed that in a co-culture with EZH2−/− naive CD8+ T-cells or chemical EZH2 inhibition in human cells, T-cells maintained memory differentiation, and increased terminal effector differentiation compared with control samples, suggesting that effector T-cell populations may not be impacted by EZH2 inhibitors, at least in short treatment protocols [237]. Here, CD8A is linked to melanoma.